Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics (2022)

First Author: Quinn T
Attributed to:  MICA: A new paradigm for testing pathway tractability in lung disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.103856

PubMed Identifier: 35152152

Publication URI: http://europepmc.org/abstract/MED/35152152

Type: Journal Article/Review

Parent Publication: eBioMedicine

ISSN: 2352-3964